Pacciclovir is a mixture of 2 PF tablets and 1 ritonavir tablets. PF prevents virus replication by blocking the activity of COVID-19 3CL protease, while ritonavir helps to slow down PF metabolism. Ritonavir plays an auxiliary role here. Before Paxlovid came out, ritonavir was also used in other drug combinations to slow down the metabolism of the main drug, so the most important component of Paxlovid and Pfizer's original was PF.
Development history
On October 22nd, 20021year1local time, 1 1, the US Food and Drug Administration (FDA) urgently authorized (EUA) a new drug, which was listed in Pfizer, the United States, to pack the nimatvir tablets together with ritonavir tablets in Paxlovid@. It can be used to treat mild and moderate adults, children, adult patients with age ≥ 12 and body mass ≥40 kg in novel coronavirus, and patients with high risk of serious diseases.
The preliminary results of the third phase clinical trial show that compared with placebo, the risk of hospitalization and death caused by any cause can be reduced by 89% for patients who receive treatment within 3 days after symptoms appear.
Reference to the above content: Baidu Encyclopedia -Paxlovid